The Comparative Immunotherapy Program led by Penn Vet’s Nicola Mason is redefining how therapies are developed and tested—uniting human and veterinary medicine to move promising immunotherapies forward.
Researchers from the School of Veterinary Medicine and Perelman School of Medicine have shown that invariant natural killer T cells from a healthy donor can persist in MHC-mismatched canines, demonstrating…
Translating Emerging Cancer Science into Effective Therapies Beyond being devoted companions, dogs share essential aspects of their biology with humans. While cancer scientists frequently use cell lines and rodent…
The interview highlighted Dr. Mason’s role in leading clinical trials that evaluated a novel Listeria-based vaccine to treat pet dogs with osteosarcoma, a common canine bone cancer.
